Latest news from
CNX Therapeutics

CNX Therapeutics is committed to having a positive impact on society, and we are proud to announce our first key milestone in our mission to take a pioneering approach to ESG; we are now participants to the UN Global Compact, a voluntary leadership platform for the development, implementation and disclosure of responsible business practices.

We are proud to announce that Sarah Morbey has joined CNX Therapeutics as Director of Legal Affairs & ESG. Sarah is a UK-qualified lawyer and company secretary, with almost 15 years of experience in the healthcare industry. Sarah joins CNX from McKesson where she was Lead Counsel within the MGPSL Business Unit, having previously held roles at Walgreens Boots Alliance and The Francis Crick Institute.

CNX Therapeutics is proud to announce that Ben Moore has joined CNX Therapeutics as our Vice President, Corporate Development. Ben has worked in the pharmaceutical industry for over 15 years and joins from Mundipharma International where he was Senior Director, Corporate and Business Development.

CNX Therapeutics is delighted to welcome Lee Debenham as our new Director of Scientific Affairs. Lee has worked in the pharmaceutical industry for 24 years and joins CNX from Bristol-Myers Squibb where he was Associate Director RCEE, and previously held roles at Celgene and Allergan.

CNX Therapeutics has embarked on its buy-and build strategy, successfully completing the acquisition of Synchrony Pharma, a company specialising in the development and commercialisation of niche injectable pharmaceuticals.

CNX Therapeutics is delighted to announce that Jeremy Devaney has joined CNX Therapeutics as Vice President, Commercial Operations.

Our new office is within LABS House, a modern and well-equipped serviced office building offering a number of amenities and communal spaces. We believe that this flexible and collaborative way of working will be the ideal environment for us to achieve our goal of building a successful European business.